Mohammad Abdollahi
Mohammad Abdollahi
Mohammad Abdollahi (MA) acquired a PharmD in 1988 from the Tehran University of Medical Sciences (TUMS) and was then completed a PhD in Pharmacology and Toxicology in 1994 from the same university; he gained a postdoc training at the University of Toronto in 2001. Since 1988, MA has worked as an academic at TUMS and has studied in the fields of Pharmacy and Medical Sciences, specifically Evidence-Based Medicine/Systematic Review/Meta-Analysis and Mechanistic Toxicology. Since 2003 he has acquired full professorship at TUMS.
MA has contributed to many journals as an author, advisor, editor and reviewer. So far, MA has published more than 550 papers and contributed in several books. MA listed in 1% top world scientists of ESI/ISI, is a prizer of IAS-COMSTECH 2005 in Pharmacology and Toxicology. MA is Editor-in-Chief of two prestigious TUMS Journals in the field of Medicine and Pharmaceutical Sciences from Elsevier and Biomed Central, respectively. Currently, MA is a Council Trustee Member of COPE (Committee on Publication Ethics). Evidence-Based Medicine/Systematic Review/Meta-Analysis is one of main research areas and field of expertise of MA. The contribution of MA to this field is attested to by an extensive array of papers in prestigious scientific journals. MA has conceived and supervised many Meta-Analyses/Systematic Reviews in the fields of Medical/Pharmacological Sciences including Gastrointestinal Disorders, Diseases related to Endocrinal Dysfunctions (Lipid/Metabolism/Diabetes), Cost-Effectiveness of drugs, etc. MA is a Member in two Cochrane Systematic Review Groups including The Inflammatory Bowel Disease and Functional Bowel Disorders and The Pregnancy and Childbirth. Additionally, by doing major review studies, MA has uncovered critical mechanistic connections between the toxicity of chemicals and the etiology of human diseases. MA believes that although the practice of medicine has a relatively long heritage and there have been significant leaps made in understanding the disease etiology, there are still major gaps in learning the efficacy of drugs in large scale in various aspects. Conducting Systematic Review/Meta-Analysis studies will help scientists to better understanding the etiology of diseases and justification of the efficacy of drugs in the way to advise clinical practitioners and patients.

Lipid and Blood Pressure
Meta-analysis Collaboration Group
Zeromskiego 113
90-549 Lodz, Poland
Phone/Fax: +48 42 639 37 71
© 2018 LBPMC. All rights reserved.